SEK1807.8m market cap
SEK34.8 last close
BONESUPPORT is an orthobiologics company that has commercialised three synthetic bone graft substitutes and has several other projects in R&D. The marketed products, CERAMENT BVF, CERAMENT G (gentamicin) and CERAMENT V (vancomycin), are intended to help orthopaedic surgeons manage bone voids and defects after injuries or diseases affecting bones.
Investment summary
BONESUPPORT’s investment case rests on three strategic pillars: effective commercial organisation, products backed by clinical data and R&D innovation. The company is selling CERAMENT bone void filler (BVF) in the US and Europe, and two antibiotic-eluting BVF products CERAMENT G/V in Europe. BONESUPPORT terminated its agreement with its exclusive distributor in the US and has since set up a network of its own independent distributors to promote CERAMENT BVF in the US. The company signed agreements with MTF Biologics and Collagen Matrix to grow its product offering sold through its US platform, and has launched a DBM product BONIFY.
Y/E Dec |
Revenue (SEKm) |
EBITDA (SEKm) |
PBT (SEKm) |
EPS (öre) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 129.3 | (98.1) | (127.1) | (321.63) | N/A | N/A |
| 2018A | 96.6 | (172.8) | (174.1) | (344.64) | N/A | N/A |
| 2019E | 199.9 | (142.1) | (142.9) | (274.86) | N/A | N/A |
| 2020E | 298.9 | (76.5) | (81.2) | (153.06) | N/A | N/A |
| Last updated on 21/10/2019 | ||||||
Industry outlook
Innovation is one of the key strategic directions for BONESUPPORT to differentiate its products from competitors offering commodity-like bone graft substitutes. The company has gathered data and is undertaking clinical trials to support the claims of its marketed products.
Last updated on 21/10/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (SEKm) | 87.6 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Emil Billbäck | CEO |
| Håkan Johansson | CFO |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma